Physician profile
Hao Yang
NPI 1124472683
$2,948.01
in general payments reported to CMS, 2019-2025
21 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.40 · 2020: $297 · 2021: $264 · 2022: $286 · 2023: $651 · 2024: $839 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $543.45 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $360.68 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $320.66 | 2021-2025 | |
| Abbott Laboratories | $281.65 | 2020-2025 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.31 | 2019-2025 | Jardiance |
| Amgen INC. | $253.21 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $237.57 | 2021-2024 | Xarelto |
| Abiomed | $142.07 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.05 | 2021 | |
| Amarin Pharma, INC. | $77.46 | 2021 | |
| Scpharmaceuticals INC. | $75.22 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $45.35 | 2023-2025 | Camzyos |
| Novo Nordisk INC | $44.68 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lantheus Medical Imaging, INC. | $44.61 | 2020 | |
| Philips North America LLC | $30.83 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $24.54 | 2021-2022 | |
| Edwards Lifesciences Corporation | $24.30 | 2024 | Hemosphere |
| Kiniksa Pharmaceuticals International, Plc | $23.00 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $21.18 | 2023 | Amvuttra |
| Bridgebio Pharma, INC. | $18.54 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $17.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hao Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.